SCHEMBL8286315

SCHEMBL8286315

O=C(CCCCCC(=O)N(CC(=O)Nc1ccccc1)CC(=O)Nc1ccccc1)NO

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 16/20 0.72
▸ HDAC6 Q9UBN7 10/20 0.72
▸ HDAC2 Q92769 10/20 0.72
▸ HDAC4 P56524 9/20 0.72
▸ HDAC7 Q8WUI4 9/20 0.72
▸ HDAC11 Q96DB2 9/20 0.72
▸ HDAC8 Q9BY41 9/20 0.72
▸ HDAC9 Q9UKV0 9/20 0.72
▸ HDAC5 Q9UQL6 9/20 0.72
▸ HDAC3 O15379 8/20 0.72
▸ HDAC10 Q969S8 8/20 0.72
▸ EGFR P00533 2/20 0.72
▸ KDM4E B2RXH2 1/20 0.72
▸ BRD4 O60885 1/20 0.72
▸ NCOR1 O75376 1/20 0.72
▸ NR1I2 O75469 1/20 0.72
▸ CYP3A4 P08684 1/20 0.72
▸ LTA4H P09960 1/20 0.72
▸ NR0B1 P51843 1/20 0.72
▸ PLK1 P53350 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8285469 0.90 HDAC1 (0.59) HDAC1HDAC6HDAC2HDAC4HDAC7
SCHEMBL8286593 0.88 HDAC1 (0.65) HDAC1HDAC6HDAC2HDAC4HDAC7
SCHEMBL8284500 0.86 HDAC1 (0.66) HDAC1HDAC6HDAC2HDAC4HDAC7
SCHEMBL8286918 0.86 HDAC1 (0.74) HDAC1HDAC6HDAC2HDAC4HDAC7
SCHEMBL8285419 0.86 HDAC1 (0.61) HDAC1HDAC6HDAC2HDAC4HDAC7
SCHEMBL8285326 0.86 HDAC1 (0.61) HDAC1HDAC6HDAC2HDAC4HDAC7
SCHEMBL8286923 0.86 HDAC1 (0.63) HDAC1HDAC6HDAC2HDAC4HDAC7
SCHEMBL23055010 0.85 HDAC1 (1.00) HDAC1HDAC6HDAC2HDAC4HDAC7
SCHEMBL8261596 0.85 HDAC1 (1.00) HDAC1HDAC6HDAC2HDAC4HDAC7
SCHEMBL19754407 0.85 HDAC1 (1.00) HDAC1HDAC6HDAC2HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023718-A1 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives ATON PHARMA, INC. (US) 2009-01-22 — — US disclosed
US-20090023718-A1 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives ATON PHARMA, INC. (US) 2009-01-22 — — US disclosed
WO-2005053610-A2 DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATIVES ATON PHARMA, INC. (US) 2005-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023718-A1 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives AADAC, BRDT, HDAC5 HDAC1 5/4885HDAC6 10/4885HDAC2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback